IO Frontiers World 2019


Christopher Bravery

Dr Christopher Bravery

Director, Advanced Biologicals Ltd

Christopher founded Consulting on Advanced Biologicals Ltd at the end of 2009 in order to focus his activities within the Regenerative Medicine sector.  CAB Ltd provides EU regulatory services to the regenerative medicine industry in addition to business and regulatory research and analysis to identify and focus on the real barriers to commercialisation of regenerative medicine.  Christopher has spent most of his career working in regenerative medicine: starting with a PhD in xenotranplantation immunology he first moved into industry in 1998 when he joined Imutran Ltd (A Novartis Pharma AG Co.) developing novel transgenic pigs to treat human organ failure.  Following the closure of Imutran, Christopher moved to Intercytex and subsequently made the transition to regulatory affairs by joining the MHRA as a quality (CMC) assessor (biologicals and biotechnology unit). During this time Christopher was involved with National implementation of the new Advanced Therapies Regulation and also involved through his participation in the CHMP’s cell products working party (CPWP) in implementation at the EMA level including drafting guidelines. 


Selected Publications

The Delivery of Regenerative Medicines and Their Impact on Healthcare (2010)
Chapter 19: A Catalyst for Change. Regulating Regenerative Medicines in Europe
CRC Press Editor(s):Catherine Prescott; Dame Julia Polak.
Regulating interface science Healthcare products: myths and uncertainties
J. R. Soc. Interface December 6, 2010 7 Suppl 6 S789-S795

PAS 83:2012 (BSI), Developing human cells for clinical applications in the European Union and the United States of America. Guide.
Free Download

Standards Can Help Bring Cell Therapy Products to Market
Ben Sheridan, Glyn Stacey, Alison Wilson, Patrick Ginty, Christopher Bravery, Damian Marshall
BioProcess International, Vol. 10, No. 4, April 2012, pp. 18–21  

Potency assay development for cellular therapy products: an ISCT* review of the requirements and experiences in the industry".
Christopher A. Bravery, Jessica Carmen, Timothy Fong, Wanda Oprea, Karin H.Hoogendoorn, Juliana Woda, Scott R. Burger, Jon A. Rowley, Mark L. Bonyhadi, Wouter Van't Hof
Cytotherapy Volume 15, Issue 1 , Pages 9-19.e9, January 2013

"Reference materials for cellular therapeutics
Christopher A. Bravery, Anna French
Cytotherapy. 2014 Sep;16(9):1187-96.

Do human leukocyte antigen-typed cellular therapeutics based on induced pluripotent stem cells make commercial sense?
Stem Cells Dev. 2015 Jan 1;24(1):1-10.

Also contributed to:

PAS 93:2011 Characterization of human cells for clinical applications. Guide
Free Download.

PAS 84:2012, Cell therapy and Regenerative medicine glossary
Free Download

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy